COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders
| Autor: | N. Veselinović, Jovana Ivanovic, Olivera Tamas, Sarlota Mesaros, Vanja Jovicevic, Jelena Drulovic, Nikola Momcilovic, Tatjana Pekmezovic, Marko Andabaka |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Pediatrics
medicine.medical_specialty COVID-19 Vaccines NMOSD Population Article 03 medical and health sciences 0302 clinical medicine Case fatality rate medicine Humans 030212 general & internal medicine education Adverse effect Prospective cohort study education.field_of_study Neuromyelitis optica business.industry SARS-CoV-2 Neuromyelitis Optica Vaccination COVID-19 General Medicine medicine.disease 3. Good health Pneumonia Neurology Adverse events Cohort Neurology (clinical) business 030217 neurology & neurosurgery |
| Zdroj: | Multiple Sclerosis and Related Disorders |
| ISSN: | 2211-0356 2211-0348 |
| Popis: | Background Reports on outcomes of COVID-19 in patients with neuromyelitis optica spectrum disorder (NMOSD) are scarce, as well as those related to the safety profile of the vaccines in this population. The aim of this survey is to present demographic and clinical characteristics of patients with NMOSD who developed COVID-19 and safety data of the COVID-19 vaccines in these persons. Methods This study comprise all patients from the Hospital registry of NMOSD, of the Clinic of Neurology in Belgrade, who fulfilled the 2015 NMOSD diagnostic criteria, and who after invitation by phone call, from April 10 to May 10, 2021, accepted to participate and provide information regarding COVID-19 and vaccination against Sars-CoV-2 (n = 53). Results Sixteen out of 53 enrolled NMOSD patients were diagnosed with COVID-19. In three cases (18.8%), severity of COVID-19 clinical manifestations warranted hospitalization, and one of these patients, died due to COVID-19 (case fatality ratio = 6.25%), after invasive mechanical ventilation. The remaining two patients had grade II COVID -19 severity and were hospitalized because of pneumonia, not requiring supplemental oxygen. Median EDSS in patients requiring hospitalization was 4.5, and in the non-hospitalized group, it was 3.0. Nine out of 53 patients received two doses of vaccine against Sars-Cov-2 (8 Sinopharm and one Pfizer). Pain at the site of application was the only vaccine-related adverse effect. Conclusions Our survey indicates overall favourable COVID-19 outcome and encouraging safety profile of the vaccines in persons with NMOSD, in our cohort. Prospective studies are warranted to confirm these data. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect